Michael R. Brodeur, PharmD, CGP, FASCP
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Julia C. Pallentino, MSN, JD, ARNP-BC, FAANP
Advanced Registered Nurse Practitioner
GI Associates of Tallahassee
Geronima Alday, MD
CentraState Family Medicine Residency
University of Medicine and Dentistry
0.5 Contact Hour
0.5 Prescribed Credit Medium
Chronic constipation in older adults can dramatically impact quality of life and lead to serious medical problems. The estimated prevalence of chronic constipation in the U.S. is between 2 and 27%, but increases to 40% among people over 65 years of age. Older adults are at particular risk due to additional chronic disease burdens, immobility, and/or functional limitations.
Effective management of chronic constipation requires a combination of provider and patient education, lifestyle and/or pharmacologic modifications, and the judicious use of pharmacologic and non-pharmacologic therapies.
This interactive newsletter will describe a comprehensive approach to care and outline considerations for tailoring treatment for individual patients. With an improved understanding of the condition and its management, primary, geriatric, and long-term care providers can help lessen the burden of chronic constipation and significantly improve the lives of the older adults in their care.
. Target Audience
Primary and long-term care physicians, pharmacists, nursing directors, physician assistants, and nurse practitioners involved in the care of older adults.
Upon completion of this knowledge-based educational activity, the participant should be able to:
Describe how a comprehensive approach is more likely to lead to effective treatment plans for older adults who have chronic constipation.
Outline the role of pharmacologic and non-pharmacologic management strategies for patients who have chronic constipation.
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the American Society of Consultant Pharmacists (ASCP), NADONA, and NJAFP are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
Dr. Brodeur has no relevant financial conflicts to disclose.
Dr. Pallentino discloses the following relationship:
Speaker’s Bureau: Takeda Pharmaceuticals North America, Inc.
Dr. Alday has no relevant financial conflicts to disclose.
Additional planning committee members, Medical Communications Media, ASCP, NADONA, and NJAFP staff have the following to disclose.
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.
Ms. Dornberger has no relevant financial conflicts to disclose.
Ms. Barrett has no relevant financial conflicts to disclose.
Ms. Hines has no relevant financial conflicts to disclose.
Dr. Paczolt has no relevant financial conflicts to disclose.
PHARMACY CONTINUING EDUCATION:
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-146-H01-P, has been assigned 0.5 Contact Hour (0.05 CEU).
NURSING CONTINUING EDUCATION: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 0.5 contact hour by NADONA/LTC.
PHYSICIAN CONTINUING EDUCATION: This Enduring Material activity, Clinical Insights in Geriatrics: Improving Chronic Constipation Management for Older Adults Through a Comprehensive Approach, has been reviewed and is acceptable for up to 0.50 Prescribed credit(s) by the American Academy of Family Physicians. AAFP accreditation begins September 15, 2011. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.
Partial credit cannot be awarded.
There is no fee to participate in this educational activity.
Commercial Support Statements
Supported by an education grant from Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc.
Minimum System Requirements: Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7. Or, Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to ensure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The activity will take approximately 30 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 80% or better and may be printed immediately after passing the post-test.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, NADONA, NJAFP, Sucampo Pharmaceuticals, Inc., or Takeda Pharmaceuticals North America, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.